Ipamorelin research centers on one of the most receptor-selective growth hormone secretagogues characterized to date: a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that mimics the endogenous hormone ghrelin at the growth hormone secretagogue receptor (GHSR-1a). What distinguishes Ipamorelin from earlier secretagogues in the preclinical literature is its narrow pharmacological profile: research has examined its ability to stimulate growth hormone (GH) release while showing little to no effect on adrenocorticotropic hormone (ACTH), cortisol, or prolactin. This page summarizes the mechanisms, receptor pharmacology, and research-model findings that make Ipamorelin a recurring subject in growth hormone axis studies.
Research Use Only. Ipamorelin is supplied strictly for laboratory and in-vitro research use. It is not for human or veterinary use, is not a dietary supplement, and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Nothing here constitutes medical guidance or a dosing protocol for any living subject.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide first described in the late 1990s as a member of the growth hormone secretagogue (GHS) class. Structurally, it belongs to the same functional family as GHRP-6, GHRP-2, and hexarelin, but it was specifically engineered for improved selectivity. In preclinical characterization, it was reported as the first GHS with a selectivity profile approaching that of the natural ligand ghrelin, yet without ghrelin's fatty-acid acylation requirement.
As a research compound, Ipamorelin is typically studied for its interaction with the ghrelin receptor and its downstream effect on somatotroph cells of the anterior pituitary. It is frequently investigated alongside growth hormone-releasing hormone (GHRH) analogs, a relationship explored in depth in our GHRH + Ghrelin Synergy in GH Research guide.
Mechanism: The GHSR-1a Ghrelin Pathway
Ipamorelin acts as an agonist at GHSR-1a, the G-protein-coupled receptor for ghrelin expressed on pituitary somatotrophs and in the hypothalamic arcuate nucleus. Ligand binding at GHSR-1a activates the Gq/11 signaling cascade:
- Phospholipase C (PLC) activation — receptor engagement stimulates PLC, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG).
- Intracellular calcium mobilization — IP₃ triggers Ca²⁺ release from intracellular stores, a key trigger for GH-containing vesicle exocytosis.
- Protein kinase C (PKC) signaling — DAG activates PKC, contributing to secretory tone.
- Somatostatin modulation — research models indicate GHS-class peptides can attenuate the inhibitory influence of somatostatin on GH release.
Because this pathway is distinct from the GHRH receptor's Gs/cAMP pathway, studies have examined how the two act in a complementary, often synergistic manner — a mechanistic theme detailed in our GHRH & Growth Hormone Axis: Mechanism Guide.
The Defining Angle: GH Release Without Cortisol or Prolactin
The most researched feature of Ipamorelin is its selectivity. Earlier secretagogues such as GHRP-6 and, more markedly, hexarelin were reported in preclinical work to elevate ACTH, cortisol, and prolactin alongside GH. In the original characterization studies, Ipamorelin stimulated GH release with a potency comparable to GHRP-6 but, notably, did not produce the ACTH and cortisol elevations seen with those compounds at GH-releasing doses.
Researchers have attributed this to Ipamorelin's tighter functional selectivity at the GHSR pathway relevant to somatotroph activation, with reduced off-target activity on the corticotroph and lactotroph populations that drive cortisol and prolactin output. This "clean" GH-release signature is precisely why Ipamorelin is a favored model compound when investigators want to isolate GH-axis effects without the confounding endocrine noise of stress-axis or prolactin activation.
Comparative Selectivity in the Research Literature
| Secretagogue (research compound) | GH release | Reported ACTH / cortisol effect | Reported prolactin effect |
|---|---|---|---|
| Ipamorelin | Strong | Minimal at GH-releasing levels | Minimal |
| GHRP-6 | Strong | Moderate elevation | Mild elevation |
| Hexarelin | Strong | Marked elevation | Elevation |
| GHRH analogs (e.g. CJC-1295) | Strong (different pathway) | Minimal | Minimal |
For a focused head-to-head on pathway differences and research applications, see Ipamorelin vs CJC-1295: Research Comparison.
Pulsatile Release and Receptor Pharmacology
A recurring observation in GHS research is that Ipamorelin, like ghrelin, tends to elicit GH release in a manner that respects the pituitary's pulsatile secretory architecture rather than flattening it. Studies have examined how GHSR agonism amplifies GH pulse amplitude while the underlying feedback machinery — IGF-1 and somatostatin — continues to shape the response. This is one reason researchers often pair a GHSR agonist with a GHRH analog: the two arms of the axis reinforce each other. The mechanistic and dose-scheduling rationale for such combinations is discussed in our CJC-1295 no DAC + Ipamorelin Blend Research guide.
Laboratory Handling and Reconstitution
The following is general laboratory guidance for preparing research aliquots — not a use protocol for any living subject.
- Form: Ipamorelin is supplied as a lyophilized powder, typically in 5 mg or 10 mg research vials.
- Reconstitution: Bacteriostatic or sterile water is commonly used to reconstitute lyophilized peptide for in-vitro work. Introduce solvent slowly against the vial wall; avoid vigorous agitation, which can shear the peptide.
- Storage: Lyophilized material is generally stored at −20 °C and protected from light. Reconstituted solutions are typically refrigerated (2–8 °C) and used within a limited window to preserve integrity.
- Stability: Repeated freeze-thaw cycles should be minimized; aliquoting before freezing is standard practice to reduce degradation.
- Purity verification: Each research lot should be accompanied by a third-party Certificate of Analysis (COA) confirming ≥99% purity via HPLC and mass spectrometry.
Explore the research-grade product and its COA on the Ipamorelin 5mg / 10mg page.
Where Ipamorelin Fits in Secretagogue Research
Within the broader class of Growth Hormone Secretagogue Peptides, Ipamorelin occupies the niche of a selective, low-off-target GHSR probe. Its value to researchers is less about raw potency — several compounds match or exceed it — and more about the clean experimental window it provides. When an investigator needs to attribute an observed effect specifically to GH-axis activation, a secretagogue that doesn't simultaneously spike cortisol and prolactin removes a major source of confounding, which is why Ipamorelin remains a reference compound in GH-release model design.
Summary
Ipamorelin is a selective GHSR-1a agonist and ghrelin mimetic studied for its ability to stimulate growth hormone release through the PLC/IP₃/Ca²⁺ pathway while showing minimal impact on ACTH, cortisol, and prolactin in preclinical models. This receptor selectivity is its defining research characteristic. All discussion here is mechanistic and pertains to laboratory research only.